Bulletin from Annual General Meeting of SciBase Holding AB (publ) on 16 May 2016

STOCKHOLM--()--SciBase (STO:SCIB)

At the annual general meeting of SciBase Holding AB (publ) on 16 May 2016 in Stockholm the shareholders adopted the below resolutions.

Resolution regarding adoption of the profit and loss account and balance sheet for the company and the group as well as resolutions in respect of appropriation of profits and discharge from liability

The meeting resolved to adopt the profit and loss account and balance sheet for the group and the Company included in the annual report.

The meeting resolved to allocate the profit for the year in accordance with the board of directors’ proposal, i.e. SEK 242,298,179 was carried forward.

The meeting resolved to discharge the board members and managing director from liability for their management of the Company's affairs during the preceding financial year.

Resolution regarding the number of members of the board of directors and deputies

The meeting resolved that the Company's board of directors shall consist of six ordinary members and two deputies.

Resolution regarding the remuneration for the board of directors and the auditor

The meeting resolved that fees to the board of directors for the financial year 2016 shall be paid with SEK 150,000 to the chairman of the board and SEK 100,000 to external members of the board of directors who do not own shares, are founders or represent a larger shareholder in the Company. Board members shall, provided that the circumstances so allow from a tax perspective and that no additional costs will be incurred by the Company, be allowed to invoice the fee.

It was resolved that fees to the Company's auditor shall be paid in accordance with approved current account.

Resolution on guidelines for determination of salary and other remuneration to senior management

The meeting resolved to adopt guidelines for determination of salary and other remuneration to senior management in accordance the board’s proposal.

Resolution regarding members of the board of directors and auditor

For the time until the end of the next annual general meeting, the meeting resolved to elect Andreas Pennervall (new election) Tord Lendau (re-election), Carsten Browall (re-election), Stig 0llmar (re-election), Per Aniansson (re-election) and Renee Aguiar-Lucander (re-election) as ordinary members of the board of directors. Anna Gustafsson (new election) and Victoria Torell (new election) were elected as deputy members of the board of directors for the time until the end of the next annual general meeting. Ernst & Young AB was re-elected as auditor with Björn Ohlsson as responsible auditor for the time until the end of the next annual general meeting.

Resolution regarding appointment of nominating committee

The meeting resolved to adopt principles for the appointment the nominating committee for the annual general meeting 2017 in accordance with the nominating committee’s proposal.

Resolution regarding authorization of the board of directors to issue new shares, issuance of warrants and/or convertibles

The meeting resolved unanimously to authorize the board of directors to, during the time until the next annual general meeting, decide upon issuances of new shares, issuance of warrants and/or convertibles. New issues of shares and issues of warrants and/or convertibles may occur with or without preferential rights for shareholders of the Company and payment may be used for strategic acquisitions, and may be made either in cash and/or by way of set-off or contribution in kind or otherwise on specific terms. The number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall not exceed 820,000.

SciBase Holding AB is required to disclose the information provided herein pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on May 17, 2016.

About Skin Cancer

Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to age 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly.

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.

This information was brought to you by Cision http://news.cision.com

Contacts

SciBase
Michael Colérus
CFO
Tel: +46 70 341 34 72
E-mail: michael.colerus@scibase.com

Contacts

SciBase
Michael Colérus
CFO
Tel: +46 70 341 34 72
E-mail: michael.colerus@scibase.com